Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227B
Sponsor: Addpharma Inc.
Summary
The purpose of this study is to evaluate the efficacy and safety of co-administration of AD-227A and AD-227B in patients with essential hypertension
Official title: A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of AD-227A and AD-227B Combination Treatment in Patients with Essential Hypertension
Key Details
Gender
All
Age Range
19 Years - Any
Study Type
INTERVENTIONAL
Enrollment
251
Start Date
2024-07-31
Completion Date
2025-09
Last Updated
2025-02-04
Healthy Volunteers
No
Conditions
Interventions
AD-227A
Per Oral, 1 Tablet, Once a day for 8 weeks
AD-227B
Per Oral, 1 Tablet, Once a day for 8 weeks
AD-227C
Per Oral, 1 Tablet, Once a day for 8 weeks
Placebo of AD-227B
Per Oral, 1 Tablet, Once a day for 8 weeks
Placebo of AD-227C
Per Oral, 1 Tablet, Once a day for 8 weeks
Locations (1)
Gangnam CHA Medical Center
Seoul, South Korea